Gwangmyeong, South Korea

Kwangmin Na

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Paean Biotechnology Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kwangmin Na: Innovator in Pharmaceutical Composition

Introduction

Kwangmin Na is a notable inventor based in Gwangmyeong, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of myositis. His innovative approach has led to the development of a unique pharmaceutical composition that utilizes isolated mitochondria as an active ingredient.

Latest Patents

Kwangmin Na holds a patent for a pharmaceutical composition aimed at preventing or treating myositis. The patent is titled "PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MYOSITIS, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT." This invention highlights his commitment to advancing medical treatments and improving patient outcomes.

Career Highlights

Kwangmin Na is currently associated with Paean Biotechnology Inc., where he continues to work on innovative solutions in biotechnology. His expertise and dedication to research have positioned him as a valuable asset in the pharmaceutical industry.

Collaborations

Throughout his career, Kwangmin Na has collaborated with esteemed colleagues, including Jin Chul Paeng and Do Won Hwang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kwangmin Na's contributions to the field of pharmaceuticals, particularly through his patent on myositis treatment, underscore his role as an influential inventor. His work at Paean Biotechnology Inc. and collaborations with other professionals further enhance his impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…